Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc Announces Positive Top-Line Results From ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis


Tuesday, 31 Jul 2012 10:12am EDT 

Pfizer Inc announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA). ORAL Start, an ongoing two-year study in methotrexate (MTX)-na├»ve patients with moderate-to-severe active RA, randomized to receive tofacitinib 5 or 10 mg twice-daily (BID) as monotherapy or MTX, met its primary endpoints at both the 5 and 10 mg BID doses. Tofacitinib was found to be superior to MTX with statistically changes shown in inhibiting structural damage, as measured by change from baseline in modified Total Sharp Score (mTSS), and in reducing signs and symptoms of RA, as measured by ACR70 response rates. Both primary endpoints assessed tofacitinib versus MTX at six months. The data reported are from a planned analysis at one year. No new safety signals emerged in the ORAL Start study, and the safety profile of tofacitinib remained consistent with that seen previously in the clinical development program. Safety findings observed in the overall tofacitinib RA program include serious and other important infections, including tuberculosis and herpes zoster; malignancies, including lymphoma; decreased neutrophil counts and neutropenia; and lipid elevations. 

Company Quote

30.25
0.16 +0.53%
17 Apr 2014